NCIC CTG MA.17: Tolerability of letrozole among ethnic minority women

摘要: 6018 Background: Disease free survival was significantly improved in women receiving letrozole after standard adjuvant tamoxifen the MA.17 trial. Based on results of and other trials aromatase inhibitors early stage breast cancer, chronic inhibitor therapy, postmenopausal cancer recurrence, is now being widely employed. We analyzed toxicity according to ethnic status among enrolled MA.17. Methods: The chi-square test used for comparison rates side effects between two groups, Caucasian vs. minority (defined as all non-Caucasians). In a subset women, quality life (QOL) assessed by SF-36 Health Survey. Mean change scores QOL from baseline were compared groups summary measures domains using Wilcoxon test. Results: 352 4,708 Caucasians MA.17, which 183 2,339 randomized receive letrozole. Caucasian...